The Novel Membrane-Associated Auxiliary Factors AuxA and AuxB Modulate β-lactam Resistance in MRSA by stabilizing Lipoteichoic Acids.
Amoxicillin
/ pharmacology
Animals
Anti-Bacterial Agents
/ pharmacology
Bacterial Proteins
/ genetics
Cefoxitin
/ pharmacology
Cell Wall
/ metabolism
DNA, Bacterial
/ genetics
Drug Resistance, Bacterial
Humans
Larva
/ microbiology
Lipopolysaccharides
/ metabolism
Membrane Proteins
/ genetics
Meropenem
/ pharmacology
Methicillin-Resistant Staphylococcus aureus
/ drug effects
Microbial Sensitivity Tests
Models, Animal
Moths
/ microbiology
Mutation
Octoxynol
/ pharmacology
Oxacillin
/ pharmacology
Penicillin-Binding Proteins
/ metabolism
Peptidoglycan
/ metabolism
Phenotype
Staphylococcal Infections
/ drug therapy
Teichoic Acids
/ metabolism
Virulence
beta-Lactam Resistance
beta-Lactams
/ pharmacology
antibiotic resistance
auxA
auxB
auxiliary factor
lipoteichoic acid
methicillin-resistant Staphylococcus aureus
β-lactam resistance
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
02
11
2020
revised:
08
12
2020
accepted:
19
12
2020
pubmed:
28
1
2021
medline:
14
9
2021
entrez:
27
1
2021
Statut:
ppublish
Résumé
A major determinant of β-lactam resistance in methicillin-resistant Staphylococcus aureus (MRSA) is the drug insensitive transpeptidase, PBP2a, encoded by mecA. Full expression of the resistance phenotype requires auxiliary factors. Two such factors, auxiliary factor A (auxA, SAUSA300_0980) and B (auxB, SAUSA300_1003), were identified in a screen against mutants with increased susceptibility to β-lactams in the MRSA strain, JE2. auxA and auxB encode transmembrane proteins, with AuxA predicted to be a transporter. Inactivation of auxA or auxB enhanced β-lactam susceptibility in community-, hospital- and livestock-associated MRSA strains without affecting PBP2a expression, peptidoglycan cross-linking or wall teichoic acid synthesis. Both mutants displayed increased susceptibility to inhibitors of lipoteichoic acid (LTA) synthesis and alanylation pathways and released LTA even in the absence of β-lactams. The β-lactam susceptibility of the aux mutants was suppressed by mutations inactivating gdpP, which was previously found to allow growth of mutants lacking the lipoteichoic synthase enzyme, LtaS. Using the Galleria mellonella infection model, enhanced survival of larvae inoculated with either auxA or auxB mutants was observed compared with the wild-type strain following treatment with amoxicillin. These results indicate that AuxA and AuxB are central for LTA stability and potential inhibitors can be tools to re-sensitize MRSA strains to β-lactams and combat MRSA infections.
Identifiants
pubmed: 33503451
pii: S0924-8579(21)00008-X
doi: 10.1016/j.ijantimicag.2021.106283
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
DNA, Bacterial
0
Lipopolysaccharides
0
Membrane Proteins
0
Penicillin-Binding Proteins
0
Peptidoglycan
0
Teichoic Acids
0
beta-Lactams
0
lipoteichoic acid
56411-57-5
Cefoxitin
6OEV9DX57Y
Amoxicillin
804826J2HU
Octoxynol
9002-93-1
Meropenem
FV9J3JU8B1
Oxacillin
UH95VD7V76
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106283Subventions
Organisme : Austrian Science Fund FWF
ID : P 29304
Pays : Austria
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.